Corneal opacities associated with NTBC treatment
- PMID: 12140036
- DOI: 10.1016/s0002-9394(02)01532-5
Corneal opacities associated with NTBC treatment
Abstract
Purpose: To describe a patient with hereditary tyrosinemia type I (HHT-I) treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) who developed corneal opacities.
Methods: A 14-month-old patient was diagnosed with HHT-I and began treatment with NTBC. Her serial ocular examinations were normal until age 4 years, when she developed ocular discomfort and was found to have bilateral, linear, branching subepithelial corneal opacities.
Results: Over the next 3 years, the extent of the opacities fluctuated, and increased opacities correlated with periods of poor compliance with a restricted protein diet. Serum tyrosine levels remained elevated at 238 to 602 umol/L (normal 26 to 83) throughout the duration of NTBC treatment.
Conclusion: Corneal opacities are a potential consequence of NTBC treatment for HHT-I. The lesions probably result from elevated serum and ocular tyrosine levels due to inhibition of the tyrosine catabolic pathway and poor dietary compliance.
Similar articles
-
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364-4. Paediatr Drugs. 2019. PMID: 31667718 Free PMC article. Review.
-
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.J Inherit Metab Dis. 2003;26(1):13-6. doi: 10.1023/a:1024011110116. J Inherit Metab Dis. 2003. PMID: 12872835 Clinical Trial.
-
Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):e5-7. doi: 10.1097/MPG.0b013e3182a27463. J Pediatr Gastroenterol Nutr. 2015. PMID: 23838819 No abstract available.
-
Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.Cornea. 2013 Jan;32(1):91-4. doi: 10.1097/ICO.0b013e318243e474. Cornea. 2013. PMID: 22495034
-
Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).J Inherit Metab Dis. 1998 Aug;21(5):507-17. doi: 10.1023/a:1005410820201. J Inherit Metab Dis. 1998. PMID: 9728331 Review.
Cited by
-
Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria.JIMD Rep. 2021 Nov 9;63(1):41-49. doi: 10.1002/jmd2.12255. eCollection 2022 Jan. JIMD Rep. 2021. PMID: 35028270 Free PMC article.
-
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364-4. Paediatr Drugs. 2019. PMID: 31667718 Free PMC article. Review.
-
Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.BMJ Case Rep. 2012 Nov 30;2012:bcr2012006301. doi: 10.1136/bcr-2012-006301. BMJ Case Rep. 2012. PMID: 23203167 Free PMC article.
-
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.Mol Genet Metab. 2011 Aug;103(4):307-14. doi: 10.1016/j.ymgme.2011.04.016. Epub 2011 May 6. Mol Genet Metab. 2011. PMID: 21620748 Free PMC article. Clinical Trial.
-
Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.Nutrients. 2020 Dec 31;13(1):134. doi: 10.3390/nu13010134. Nutrients. 2020. PMID: 33396520 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
